<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Hematol</journal-id><journal-title-group><journal-title>Annals of Hematology</journal-title></journal-title-group><issn pub-type="ppub">0939-5555</issn><issn pub-type="epub">1432-0584</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35411439</article-id><article-id pub-id-type="pmc">PMC9001015</article-id><article-id pub-id-type="publisher-id">4799</article-id><article-id pub-id-type="doi">10.1007/s00277-022-04799-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>COVID-19: impact of vaccination in myeloma patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6629-1766</contrib-id><name><surname>Hoornaert</surname><given-names>E.</given-names></name><address><email>Ellen.hoornaert@uclouvain.be</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dachy</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hansenne</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bailly</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Maanen</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gruson</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Vekemans</surname><given-names>M-C.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.48769.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0461 6320</institution-id><institution>Department of Internal Medicine and Infectious Diseases, </institution><institution>Cliniques universitaires Saint Luc, </institution></institution-wrap>10 avenue Hippocrate, 1200 Woluwe Saint Lambert, Brussels, Belgium </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.48769.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0461 6320</institution-id><institution>Department of Hematology, </institution><institution>Cliniques universitaires Saint Luc, </institution></institution-wrap>1200 Brussels, Belgium </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.48769.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0461 6320</institution-id><institution>Statistical Support Unit, </institution><institution>King Albert II Institute, Cliniques Universitaires Saint Luc, </institution></institution-wrap>1200 Brussels, Belgium </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.48769.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0461 6320</institution-id><institution>Department of Laboratory Medicine, </institution><institution>Cliniques universitaires Saint Luc, </institution></institution-wrap>1200 Brussels, Belgium </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="ppub"><year>2022</year></pub-date><volume>101</volume><issue>7</issue><fpage>1607</fpage><lpage>1608</lpage><history><date date-type="received"><day>13</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">Dear Editor,</p><p id="Par2">The worldwide COVID-19 pandemic represents an unprecedented crisis that affects the entire medical community and appears to be a devastating infection in patients with hematological disorders, including myeloma (MM) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Vaccination is therefore crucial in this population [<xref ref-type="bibr" rid="CR4">4</xref>]. Seroconversion after COVID-19 has been shown to be lower in MM patients compared to the general population. The same is expected after vaccination, as different studies have already reported a lower antibody response after anti-SARS-CoV-2 vaccination in this group [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par3">We investigated the impact of anti-SARS-CoV-2 vaccination in patients with MM or related disorders, excluding MGUS. Immunization was assessed after two shots of either a mRNA (Pfizer&#x000ae;/Moderna&#x000ae;) or a viral vector (Astra Zeneca&#x000ae;) vaccine, using the Elecsys&#x000ae; immunoassay performed on cobas&#x000ae;8000 (Roche Diagnostics&#x000ae;) that measures anti-SARS-CoV-2 antibodies including IgG.</p><p id="Par4">From March 2020 to September 2021, we determined the serological status at day 30 (median 36, range 1&#x02013;148), of the first 164 patients with plasma cell dyscrasias that completed vaccination. Among them, 114 were affected by MM, 26 by asymptomatic MM, 8 by MGRS, 16 by AL amyloidosis.</p><p id="Par5">The characteristics of our cohort were as followed: median age of 69 (range 35&#x02013;89), median IgG level of 700&#x000a0;mg/dL (range 80&#x02013;1840), median CD4/CD8 levels of 530/&#x003bc;L (range 58&#x02013;1668), and 398/&#x003bc;L (range 33&#x02013;4556), respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Patients characteristics and results</p></caption><graphic xlink:href="277_2022_4799_Fig1_HTML" id="MO1"/></fig></p><p id="Par6">One hundred fifty patients (92%) developed regular antibodies confirmed by the presence of the receptor-binding domain of the spike protein (RBD) antibodies, while 23 (14%) presented nucleocapsid protein (N) antibodies, suggesting a previous contact with the virus. Among these, 12 had a history of a positive RT-PCR nasopharyngeal swab and 11 were fortuitously found to be positive in the absence of any clinical manifestation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par7">Thirteen patients failed to develop any immunization; all had received immunosuppressive therapies (renal transplantation in 1, long-term corticosteroids in 2, cyclophosphamide in 4, anti-CD20 monoclonal antibodies in 4, both in 2) or multiple lines of therapies in 1. We failed to identify any link with immunoparesis or CD4/CD8 levels. As well, there was no correlation between RBD antibody and CD4 levels. All patients tested after the third dose develop immunization except those exposed to anti-CD20 therapies in the previous 12&#x000a0;months. Only one patient underwent an interferon-gamma-release assay testing that was negative.</p><p id="Par8">Nowadays, with an 8-month median follow up after vaccination, if only 5 patients experienced a mild form of COVID-19 during the Delta-variant wave, more patients (<italic>n</italic>&#x02009;=&#x02009;12) are tested positive with the emergence of the omicron variant, but there were no significant clinical manifestations, hospitalizations, or deaths.</p><p id="Par9">In conclusion, SARS-CoV-2 vaccination provided an adequate coverage in our MM population during the delta wave since only five patients developed a mild infection after vaccination. Seroconversion was however clearly affected by the anti-MM treatment. With the appearance of the omicron variant, we observed an upsurge of cases, even of benign evolution, which questions this protection. Whether non-responding patients will eventually develop T cell protection against COVID-19 remains also to be answered, as well as the positivity cutoff that measures neutralizing antibodies, the optimal vaccination schedule, particularly in the context of immunodeficiency, and diverse anti-MM therapies.</p></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contribution</title><p>E.H., F.D., A.V.M., and M.C.V. analyzed the data.</p><p>E.H., F.D., and M.C.V. wrote the manuscript.</p><p>F.D., A.H., S.B., and M.C.V. collected the data and obtained the consent of each patient.</p><p>All authors approved the final manuscript.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethical approval</title><p id="Par10">All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.</p></notes><notes id="FPar2"><title>Consent to participate</title><p id="Par11">Informed consent was obtained from all induvial patients included in the study.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par12">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufour</surname><given-names>I</given-names></name><etal/></person-group><article-title>Impact of COVID-19 on myeloma patients</article-title><source>Ann Hematol</source><year>2020</year><volume>99</volume><fpage>1947</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1007/s00277-020-04147-7</pub-id><pub-id pub-id-type="pmid">32577846</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>G</given-names></name><etal/></person-group><article-title>Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy</article-title><source>J Haematol</source><year>2020</year><volume>190</volume><fpage>83</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/bjh.16874</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hultcranz</surname><given-names>M</given-names></name><etal/></person-group><article-title>COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers</article-title><source>Blood Cancer Discovery</source><year>2020</year><volume>1</volume><fpage>234</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1158/2643-3230.BCD-20-0102</pub-id><pub-id pub-id-type="pmid">34651141</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>H</given-names></name><etal/></person-group><article-title>Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network</article-title><source>Leukemia</source><year>2021</year><volume>35</volume><fpage>31</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-01016-0</pub-id><pub-id pub-id-type="pmid">32814840</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>S</given-names></name><etal/></person-group><article-title>Response to first vaccination against SARS-CoV-2 patients with multiple myeloma</article-title><source>Lancet Haematol</source><year>2021</year><volume>6</volume><fpage>389</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(21)00110-1</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimpinelli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution</article-title><source>J Haematol Oncol</source><year>2020</year><volume>14</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01090-6</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oekelen</surname><given-names>V</given-names></name><etal/></person-group><article-title>Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>1028</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.06.014</pub-id><pub-id pub-id-type="pmid">34242572</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terpos</surname><given-names>E</given-names></name><etal/></person-group><article-title>The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment</article-title><source>Blood Cancer J</source><year>2021</year><volume>11</volume><issue>8</issue><fpage>138</fpage><pub-id pub-id-type="doi">10.1038/s41408-021-00530-3</pub-id><pub-id pub-id-type="pmid">34341335</pub-id></element-citation></ref></ref-list></back></article>
